Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.38 |
| ▸ | CD22 | P20273 | 11/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NEU4 | Q8WWR8 | 1/20 | 0.34 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.34 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.34 |
| ▸ | NEU2 | Q9Y3R4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10018768 | 0.94 | NANP (0.37) | NANPCD22NEU4NEU1NEU3 | |
| SCHEMBL13948883 | 0.94 | NANP (0.37) | NANPCD22NEU4NEU1NEU3 | |
| SCHEMBL12341486 | 0.88 | NANP (0.48) | NANPCD22L3MBTL1NEU3 | |
| SCHEMBL5531927 | 0.88 | CD22 (0.37) | NANPCD22 | |
| SCHEMBL13931893 | 0.88 | NANP (0.39) | NANPCD22L3MBTL1 | |
| SCHEMBL15677307 | 0.87 | NANP (0.51) | NANPCD22 | |
| SCHEMBL12341441 | 0.87 | NANP (0.37) | NANPCD22L3MBTL1 | |
| SCHEMBL12730475 | 0.87 | NANP (0.44) | NANPCD22 | |
| SCHEMBL13402355 | 0.87 | NANP (0.37) | NANPCD22L3MBTL1 | |
| SCHEMBL12341443 | 0.87 | NANP (0.44) | NANPCD22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050304-B2 | Methods of treatment using glycopegylated G-CSF | RATIOPHARM GMBH (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8916360-B2 | Glycopegylated erythropoietin | NOVO NORDISK A/S (DK) | 2014-12-23 | — | — | US | disclosed |
| US-20120107867-A1 | GLYCOPEGYLATED ERYTHROPOIETIN | NOVO NORDISK A/S (DK) | 2012-05-03 | — | — | US | disclosed |
| US-20100120666-A1 | METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF | BIOGENERIX AG (DE) | 2010-05-13 | — | — | US | disclosed |
| US-7276475-B2 | Remodeling and glycoconjugation of peptides | NEOSE TECHNOLOGIES, INC. (US) | 2007-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120666-A1 | METHODS OF TREATMENT USING GLYCOPEGYLATED G-CSF | CSF3R, CSF1R, SIGLEC7 | NANP 1385/4885CD22 163/4885L3MBTL1 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.